Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹127 Cr
Revenue (TTM)
₹119 Cr
Net Profit (TTM)
₹10 Cr
ROE
186.7 %
ROCE
42.2 %
P/E Ratio
13.2
P/B Ratio
7.4
Industry P/E
26.81
EV/EBITDA
7.5
Div. Yield
0 %
Debt to Equity
3.3
Book Value
₹2.1
EPS
₹2
Face value
1
Shares outstanding
47,312,741
CFO
₹26.88 Cr
EBITDA
₹31.82 Cr
Net Profit
₹-1.73 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kimia Biosciences
| -21.1 | -20.5 | -23.8 | -35.7 | -6.2 | -7.6 | -- |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Kimia Biosciences
| -24.3 | 24.4 | -14.4 | -30.2 | 20.3 | 131.6 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Kimia Biosciences
|
26.8 | 126.7 | 118.9 | 9.6 | 11.6 | 186.7 | 13.2 | 7.4 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,499.2 | 9,167.3 | 1,196.4 | 149.4 | -- | 27.5 | 61.3 | 13.1 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
No Review & Analysis are available.
Laurel Organics Ltd manufactures and sells pharmaceutical-bulk drugs in India. The company offers Benfotiamine, Cilnidipine, Gliclazide, Levosulpride, Rosuvastatin Calcium, Tranexamic Acid, Benidipine, Teneligliptin Hydrate Hydrobromide, Acotiamide,... Citicoline Sodium, Luliconazole, Deflazacort, Voglibose, Oxaceprol, Ursodeoxycholic Acid, Bacitracin Zinc, Isotretinoin, and Tretinoin, as well as vitamin B1, calcium channel blocker, central stimulant/nootropic agent, and choleretic agent. It also provides products for various therapeutic categories, which comprise antidiabetic, antipsychotic, antihyperlipidemic, hemostatic, antihypertensive, antidiabetic, antiemetic, anti-fungal, anti-inflammatory, and anti-acne. The company was incorporated in 1993 and is based in New Delhi, India. Laurel Organics Ltd is a subsidiary of Kimia Biosciences Ltd. Read more
Incorporated
1993
Chairman
Sameer Goel
Managing Director
Sameer Goel
Headquarters
Bhondsi, Haryana
Website
Looking for more details about Kimia Biosciences Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Kimia Biosciences Ltd is ₹26.78 (BSE) as of 02-Apr-2026 IST. Kimia Biosciences Ltd has given a return of -6.25% in the last 3 years.
The P/E ratio of Kimia Biosciences Ltd is 13.18 times as on 02-Apr-2026, a 51 discount to its peers’ median range of 26.81 times.
The P/B ratio of Kimia Biosciences Ltd is 7.44 times as on 02-Apr-2026, a 60 premium to its peers’ median range of 4.65 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
20.92
|
20.18
|
|
2024
|
0.00
|
796.60
|
|
2023
|
0.00
|
28.15
|
|
2022
|
0.00
|
11.95
|
|
2021
|
35.17
|
9.74
|
The 52-week high and low of Kimia Biosciences Ltd are Rs 86.85 and Rs 23.20 as of 04-Apr-2026.
Kimia Biosciences Ltd has a market capitalisation of ₹ 127 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Kimia Biosciences Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.87
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.